BridgeMD
CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids.
EU CTIS ID: 2025-520571-66-00
What this study is testing
To assess the extent to which the antiandrogens (enzalutamide and apalutamide) influence the pharmacokinetics of the administered corticosteroid dexamethasone.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosed prostate cancer
- Intended to begin treatment with antiandrogen therapy, -enzalutamide or apalutamide-
- Can understand all the requirements of the trial, provide informed consent, and provide authorization of use and disclosure of personal health information
- WHO performance status 0-1
You likely can't join if
- Treatment with systemic corticosteroids (ongoing or last 4 weeks), inhalations steroids, topical steroids or nasal steroids are not regarded as systemic therapies
- Treatment with health product modulating CYP3A4
- Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
- Diabetes (defined as diagnosed diabetes type I or type II)
- Previous seizure in medical history
- Other serious illness or medical condition according to the investigator, e.g., other cancer, history of peptic ulcer, or bipolar disorder.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.